ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Depakote For Epilepsy & Bipolar Disorder: Treatment & Usage Guide Released

Mission Connection has released a guide on Depakote (valproate), a medication commonly prescribed for epilepsy and bipolar disorder. The guide covers side effects, dosages, and safe discontinuation.

-- With over three million prescriptions in the United States, Depakote was one of the most commonly prescribed mood stabilizers in 2021. Mission Connection’s latest guide is intended to answer common questions about its uses, how long it takes to be effective, possible side effects, and how to safely discontinue the drug.

More information is available at https://missionconnectionhealthcare.com/mental-health/mood-stabilizers/depakote/

Depakote, also known as valproate, is one of the oldest anti-epileptic drugs in the U.S. First synthesized in 1882, the medication has been on the market since 1978, where it’s been used to reduce the intensity of manic episodes, help patients with bipolar disorder regulate their emotions, and alleviate seizures and migraines. Depakote works by increasing the brain’s levels of gamma-aminobutyric acid (GABA), a neurotransmitter that is associated with feelings of calm and relaxation and can block voltage-dependent sodium channels, which in turn suppresses high-frequency neuronal firing - bursts of electrical activity that result in seizures.

The FDA has approved Depakote for use for all the aforementioned conditions, and patients may have to take it for at least one to two weeks for noticeable effects. While the medication is effective for mood symptoms, migraines, and seizures, Mission Connection also notes that, like any long-term medication, Depakote may have side effects if used over a significant period of time.

Two common side effects include impacts to liver function and weight gain; health professionals will typically monitor the patient for these symptoms through blood tests and follow-up appointments. If Depakote is taken for months or years, it can also lead to hormone imbalances and changes in bone density or energy levels. Additionally, the medication may result in birth defects, and individuals who are planning to give birth are typically recommended to stop taking it before pregnancy.

For individuals who want to discontinue Depakote, Mission Connection says that gradual dose reduction over several weeks is required to allow the nervous system to adjust safely, minimizing the risk of withdrawal symptoms such as nausea, headaches, mood changes, or seizures. While tapering off the drug, patients should watch for returning symptoms, consider regular blood tests, and adjust the pace of their dose reduction if necessary.

Further resources and support are available at https://missionconnectionhealthcare.com/

Contact Info:
Name: Nathan Di Tomaso
Email: Send Email
Organization: Mission Connection
Address: 30310 Rancho Viejo Rd. , San Juan Capistrano, California 92675, United States
Website: https://missionconnectionhealthcare.com/

Source: PressCable

Release ID: 89175636

Should you come across any errors, concerns, or inconsistencies within this press release's content, we urge you to reach out without delay by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our committed team will promptly address your feedback within 8 hours and take appropriate measures to resolve any identified issues or guide you through the removal process. Providing accurate and dependable information remains our utmost priority.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  201.15
+2.36 (1.19%)
AAPL  263.88
+8.10 (3.17%)
AMD  203.08
-4.24 (-2.05%)
BAC  52.74
+0.19 (0.36%)
GOOG  302.82
-3.20 (-1.05%)
META  639.29
-0.48 (-0.08%)
MSFT  396.86
-4.46 (-1.11%)
NVDA  184.97
+2.16 (1.18%)
ORCL  153.97
-6.17 (-3.85%)
TSLA  410.63
-6.81 (-1.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.